Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?

References

• World Health Organization. Cancer fact sheet. 2017. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/
   Google Scholar
• La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol. 2011;8:587–596.
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148.
   PubMed Web of Science ®Google Scholar
• Yuan J. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother. Cancer. 2016;4:3.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Haanen JBAG, Punt CJA. Cancer immunotherapy-revisited. Nat Rev Drug Discov. 2011;10:591–600.
   PubMed Web of Science ®Google Scholar
• Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13:195–207.
   PubMed Web of Science ®Google Scholar
• Zaenker P, Gray ES, Ziman MR. Autoantibody production in cancer-the humoral immune response toward autologous antigens in cancer patients. Autoimmun. Rev. 2016;15:477–483.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• FDA. 2017. Press Announcements-FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma.
   Google Scholar
• Krummel BME, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996;183:2533–2540.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–1982.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Pachynski R, et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J Natl Cancer Inst. 2017;109:1–9. DOI:10.1093/jnci/djw261
   Google Scholar
• Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372–8377.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21:4286–4293.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. Avelumab (BAVENCIO). 2017. [cited Nov 1]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm547965.htm
   Google Scholar
• U.S. Food & Drug Administration. Durvalumab (Imfinzi). 2017. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm
   Google Scholar
• Cancer mutational load: The more the merrier for immune checkpoint blockade therapies. EBioMedicine 2016;13:1–2.
   PubMed Web of Science ®Google Scholar
• Mehnert JM, Monjazeb AM, Beerthuijzen JMT, et al. The challenge for development of valuable immuno-oncology biomarkers. Clin Cancer Res. 2017;23:4970–4979.
   PubMed Web of Science ®Google Scholar
• Kelderman S, Heemskerk B, van Tinteren H, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother. 2014;63:449–458.
   PubMed Web of Science ®Google Scholar
• Andrews A. Treating with checkpoint inhibitors-figure $1 million per patient. Am Health Drug Benefits. 2015;8:9.
   PubMedGoogle Scholar
• Weber JS, Dummer R, De Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119:1675–1682.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–2697.
   PubMed Web of Science ®Google Scholar
• Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
   PubMed Web of Science ®Google Scholar
• Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371–381.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–1030.
   PubMed Web of Science ®Google Scholar
• Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 2016;19:82–92.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017.
   PubMed Web of Science ®Google Scholar
• Mehta S, Shelling A, Muthukaruppan A, et al. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol. 2010;2:125–148.
   PubMedGoogle Scholar
• Gnjatic S, Bronte V, Brunet LR, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunotherapy Cancer. 2017;5:44.
   PubMed Web of Science ®Google Scholar
• Kulasingam V, Prassas I, Diamandis EP. Towards personalized tumor markers. Npj Precis Oncol. 2017;1:17.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–856.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–211.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128.
   PubMed Web of Science ®Google Scholar
• Viale G, Trapani D, Curigliano G. Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy. BioMed Res. Int. 2017;2017:1.
   Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413.
   PubMed Web of Science ®Google Scholar
• Hamid O, Schmidt H, Nissan A, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204.
   PubMed Web of Science ®Google Scholar
• Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. JCO. 2009;27:2645–2652.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinicalactivity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010;16:399–403.
   PubMed Web of Science ®Google Scholar
• Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116:1767–1775.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Estrada MV, Salgado R, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582–10510.
   PubMed Web of Science ®Google Scholar
• Simeone E, Gentilcore G, Giannarelli D, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother. 2014;63:675–683.
   PubMed Web of Science ®Google Scholar
• Verma M. Personalized Medicine and Cancer. J Pers Med. 2012;2:1–14.
   PubMedGoogle Scholar
• Duffy MJ, Sturgeon CM, Sölétormos G, et al. Validation of new cancer biomarkers: a position statement from the european group on tumor markers. Clin Chem. 2015;61:809–820.
   PubMed Web of Science ®Google Scholar
• Diamandis EP. Present and future of cancer biomarkers. Clin Chem Lab Med. 2014;52:791–794.
   PubMed Web of Science ®Google Scholar
• Diamandis EP. A repository for rare tumor markers? Clin Chem Lab Med. 2014;52:795–797.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. The exceptional responders initiative: welcoming more cases. 2015. [cited 2017 Nov 1]. Available from https://www.cancer.gov/news-events/cancer-currents-blog/2015/exceptional-responders-initiative
   Google Scholar
• Macdonald IK, Parsy-Kowalska CB, Chapman CJ. Autoantibodies: opportunities for early cancer detection. Trends Cancer. 2017;3:198–213.
   PubMed Web of Science ®Google Scholar
• Fernández Madrid F, Karvonen RL, Ensley J, et al. Spectra of antinuclear antibodies in patients with squamous cell carcinoma of the lung and of the head and neck. Cancer Detect Prev. 2005;29:59–65.
   PubMedGoogle Scholar
• Hong Y, Huang J. Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma. WJH. 2015;7:1581–1585.
   PubMed Web of Science ®Google Scholar
• Evans RL, Pottala JV, Egland KA. Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens. Cancer Prev Res. 2014;7:545–555.
   PubMed Web of Science ®Google Scholar
• Doseeva V, Colpitts T, Gao G, et al. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. J Transl Med. 2015;13:55.
   PubMed Web of Science ®Google Scholar
• Bei R, Masuelli L, Palumbo C, et al. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth. Cancer Lett. 2009;281:8–23.
   PubMed Web of Science ®Google Scholar
• Belousov PV, Kuprash DV, Nedospasov SA, et al. Autoantibodies to tumor-associated antigens as cancer biomarkers. Curr Mol Med. 2010;10:115–122.
   PubMed Web of Science ®Google Scholar
• Hansen MH, Nielsen HV, Ditzel HJ. Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol. 2002;169:2701–2711.
   PubMed Web of Science ®Google Scholar
• Tan HT, Low J, Lim SG, et al. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276:6880–6904.
   PubMed Web of Science ®Google Scholar
• Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005;4:1123–1133.
   PubMed Web of Science ®Google Scholar
• Kwek SS, Dao V, Roy R, et al. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol. 2012;189:3759–3766.
   PubMed Web of Science ®Google Scholar
• Yuan J, Adamow M, Ginsberg BA, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci. 2011;108:16723–16728.
   PubMed Web of Science ®Google Scholar
• Qin L, Smith BD, Tsai H-L, et al. Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy. Blood Cancer J. 2013;3:e145–e111.
   PubMed Web of Science ®Google Scholar
• Nyberg K. (2017). ASCO-SITC Clinical Immuno-oncology Symposium.
   Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446–451.
   PubMed Web of Science ®Google Scholar
• Canelle L, Bousquet J, Pionneau C, et al. An efficient proteomics-based approach for the screening of autoantibodies. J Immunol Methods. 2005;299:77–89.
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Ritter E, Büchler MW, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci USA. 2010;107:5088–5093.
   PubMed Web of Science ®Google Scholar
• Templin MF, Stoll D, Schwenk JM, et al. Protein microarrays: promising tools for proteomic research. Proteomics. 2003;3:2155–2166.
   PubMed Web of Science ®Google Scholar
• Heo CK, Bahk YY, Cho EW. Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Rep. 2012;45:677–685.
   PubMed Web of Science ®Google Scholar
• Andresen H, Bier FF. Peptide microarrays for serum antibody diagnostics. Methods Mol Biol. 2009;509:123–134.
   PubMedGoogle Scholar
• Masch A, Zerweck J, Reimer U, et al. Antibody signatures defined by high-content peptide microarray analysis. Methods Mol Biol. 2010;669:161–172.
   PubMedGoogle Scholar
• Kulasingam V, Smith CR, Batruch I, et al. Immuno-mass spectrometry: quantification of low-abundance proteins in biological fluids. Methods Mol Biol. 2011;728:207–218.
   PubMedGoogle Scholar
• Korbakis D, Prassas I, Brinc D, et al. Delineating monoclonal antibody specificity by mass spectrometry. J Proteomics. 2015;114:115–124.
   PubMed Web of Science ®Google Scholar